Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.
Coya Therapeutics, a clinical-stage biotechnology company, secured an option agreement in June 2022 for exclusive worldwide rights to a novel technology platform from Carnegie Mellon University. The technology platform enables exosome engineering.
The agreement will grant Coya intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids (EPHs), according to a June 15, 2022 press release. The company will use a tether-based exosome strategy that enables regulatory T-cells (Tregs) exosomes to be homed to proteins of interest while delivering select payloads into the targeted cells.
According to the release, the use of EPHs differs from traditional techniques that modify exosomes via complex molecular biology tools or degradation of exosomes' innate functionality; EPHs overcome these limitations by modifying exosomes with a DNA-cholesterol tether. By leveraging single stranded synthetic DNA with attached cholesterol, this approach binds a complementary strand of DNA to a bioactive agent. Ultimately, this allows a number of different types of cargos to be attached to the exosome surface while also tethering immune modulating cargos inside the exosome.
“This collaboration with Carnegie Mellon University further solidifies Coya’s thought leadership in the global exosome therapeutics field, beyond Treg-derived exosomes alone,” said Howard Berman, CEO, Coya Therapeutics, in the press release. “Nanoengineering exosomes with such manufacturing efficiency to produce EPHs that can be customized to any surface protein, delivering growth factors or drugs, while enhancing cellular uptake and bioactivity is the future of targeted therapies.”
Source: Carnegie Mellon University
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.